HK1254354A1 - 包括給予2-氨基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 - Google Patents
包括給予2-氨基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療Info
- Publication number
- HK1254354A1 HK1254354A1 HK18113430.1A HK18113430A HK1254354A1 HK 1254354 A1 HK1254354 A1 HK 1254354A1 HK 18113430 A HK18113430 A HK 18113430A HK 1254354 A1 HK1254354 A1 HK 1254354A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tetrahydropyridines
- trifluoro
- administration
- amino
- combination treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201500456 | 2015-08-10 | ||
DKPA201500707 | 2015-11-10 | ||
PCT/EP2016/068947 WO2017025532A1 (en) | 2015-08-10 | 2016-08-09 | Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1254354A1 true HK1254354A1 (zh) | 2019-07-19 |
Family
ID=56799425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18113430.1A HK1254354A1 (zh) | 2015-08-10 | 2018-10-19 | 包括給予2-氨基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 |
Country Status (26)
Country | Link |
---|---|
US (1) | US10004738B2 (zh) |
EP (1) | EP3334461A1 (zh) |
JP (1) | JP2018529647A (zh) |
KR (1) | KR20180035843A (zh) |
CN (1) | CN107921138A (zh) |
AR (1) | AR105656A1 (zh) |
AU (1) | AU2016305260A1 (zh) |
BR (1) | BR112017007306A2 (zh) |
CA (1) | CA2993623A1 (zh) |
CL (1) | CL2018000339A1 (zh) |
CO (1) | CO2018000711A2 (zh) |
CR (1) | CR20180093A (zh) |
DO (1) | DOP2018000039A (zh) |
EA (1) | EA201890257A1 (zh) |
EC (1) | ECSP18010534A (zh) |
HK (1) | HK1254354A1 (zh) |
IL (1) | IL257072A (zh) |
MA (1) | MA42611A (zh) |
MX (1) | MX2018001636A (zh) |
PE (1) | PE20180696A1 (zh) |
PH (1) | PH12018500300A1 (zh) |
RU (1) | RU2018104867A (zh) |
SV (1) | SV2018005628A (zh) |
TN (1) | TN2018000041A1 (zh) |
TW (1) | TW201717948A (zh) |
WO (1) | WO2017025532A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
MX2018001699A (es) | 2015-08-12 | 2018-05-07 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
MXPA04007838A (es) | 2002-02-12 | 2004-10-15 | Smithkline Beecham Corp | Derivados de nicotamida utiles como inhibidores p38. |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
SG185651A1 (en) | 2010-06-09 | 2012-12-28 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
MX2013008111A (es) | 2011-01-12 | 2013-10-30 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos. |
EA024059B1 (ru) | 2011-01-13 | 2016-08-31 | Новартис Аг | Гетероциклические производные и их применение в лечении неврологических расстройств |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するbace1阻害剤 |
US8987255B2 (en) | 2011-06-07 | 2015-03-24 | Hoffmann-La Roche Inc. | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
JP2015531401A (ja) * | 2011-10-10 | 2015-11-02 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノン骨格を有するpde9i |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
BR112014023384A8 (pt) | 2012-03-20 | 2018-01-16 | R Artis Dean | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. |
WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
WO2014134341A1 (en) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
MA39225A1 (fr) | 2014-02-19 | 2017-04-28 | H Lundbeck As | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
MX2018001699A (es) | 2015-08-12 | 2018-05-07 | H Lundbeck As | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. |
-
2016
- 2016-08-04 TW TW105124755A patent/TW201717948A/zh unknown
- 2016-08-08 US US15/231,182 patent/US10004738B2/en not_active Expired - Fee Related
- 2016-08-09 EA EA201890257A patent/EA201890257A1/ru unknown
- 2016-08-09 CA CA2993623A patent/CA2993623A1/en not_active Abandoned
- 2016-08-09 MA MA042611A patent/MA42611A/fr unknown
- 2016-08-09 TN TNP/2018/000041A patent/TN2018000041A1/en unknown
- 2016-08-09 MX MX2018001636A patent/MX2018001636A/es unknown
- 2016-08-09 JP JP2018506913A patent/JP2018529647A/ja active Pending
- 2016-08-09 CN CN201680045247.2A patent/CN107921138A/zh active Pending
- 2016-08-09 PE PE2018000223A patent/PE20180696A1/es not_active Application Discontinuation
- 2016-08-09 KR KR1020187005381A patent/KR20180035843A/ko unknown
- 2016-08-09 RU RU2018104867A patent/RU2018104867A/ru not_active Application Discontinuation
- 2016-08-09 CR CR20180093A patent/CR20180093A/es unknown
- 2016-08-09 AR ARP160102441A patent/AR105656A1/es unknown
- 2016-08-09 BR BR112017007306A patent/BR112017007306A2/pt not_active Application Discontinuation
- 2016-08-09 AU AU2016305260A patent/AU2016305260A1/en not_active Abandoned
- 2016-08-09 WO PCT/EP2016/068947 patent/WO2017025532A1/en active Application Filing
- 2016-08-09 EP EP16756631.4A patent/EP3334461A1/en not_active Withdrawn
-
2018
- 2018-01-22 IL IL257072A patent/IL257072A/en unknown
- 2018-01-25 CO CONC2018/0000711A patent/CO2018000711A2/es unknown
- 2018-02-06 CL CL2018000339A patent/CL2018000339A1/es unknown
- 2018-02-07 SV SV2018005628A patent/SV2018005628A/es unknown
- 2018-02-08 DO DO2018000039A patent/DOP2018000039A/es unknown
- 2018-02-09 PH PH12018500300A patent/PH12018500300A1/en unknown
- 2018-02-09 EC ECIEPI201810534A patent/ECSP18010534A/es unknown
- 2018-10-19 HK HK18113430.1A patent/HK1254354A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180035843A (ko) | 2018-04-06 |
CR20180093A (es) | 2018-06-05 |
AR105656A1 (es) | 2017-10-25 |
WO2017025532A1 (en) | 2017-02-16 |
PE20180696A1 (es) | 2018-04-23 |
CN107921138A (zh) | 2018-04-17 |
PH12018500300A1 (en) | 2018-08-29 |
US10004738B2 (en) | 2018-06-26 |
AU2016305260A1 (en) | 2018-02-15 |
TN2018000041A1 (en) | 2019-07-08 |
ECSP18010534A (es) | 2018-04-30 |
MA42611A (fr) | 2018-06-20 |
MX2018001636A (es) | 2018-05-07 |
CA2993623A1 (en) | 2017-02-16 |
US20170042895A1 (en) | 2017-02-16 |
EA201890257A1 (ru) | 2018-07-31 |
RU2018104867A (ru) | 2019-09-12 |
DOP2018000039A (es) | 2018-04-30 |
CL2018000339A1 (es) | 2018-07-06 |
EP3334461A1 (en) | 2018-06-20 |
SV2018005628A (es) | 2018-04-19 |
CO2018000711A2 (es) | 2018-05-10 |
IL257072A (en) | 2018-03-29 |
JP2018529647A (ja) | 2018-10-11 |
TW201717948A (zh) | 2017-06-01 |
BR112017007306A2 (pt) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264049A (en) | Compounds, preparations and methods for treating the disease | |
IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
IL264156A (en) | Compounds, preparations and methods for treating the disease | |
IL246875A0 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
ZA201708039B (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
GB201515657D0 (en) | Heart rate monitor | |
IL259246A (en) | Preparations containing pharmaceutical substances and methods of using them | |
GB2541571A (en) | Pharmaceutical compositions | |
HK1259372A1 (zh) | 治療化合物、其組合物及使用方法 | |
IL266047A (en) | Methods and preparations for the treatment of Fabry disease | |
SG11201705450SA (en) | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases | |
HK1254354A1 (zh) | 包括給予2-氨基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療 | |
IL252897A0 (en) | Indanyl compounds, pharmaceutical preparations and their medical uses | |
HK1256362A1 (zh) | 共晶、其製造方法及含有共晶的藥物 | |
HK1258999A1 (zh) | 用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物 | |
IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
HK1258765A1 (zh) | 治療性化合物、組合物和它們的使用方法 | |
IL253878A0 (en) | An effective substance for the treatment of respiratory inflammation | |
IL248428A0 (en) | Use of 3,1-propanedisulfonic acid or pharmaceutically acceptable saline to treat sarcoidosis | |
ZA201802201B (en) | Novel formulation and treatment methods | |
HRP20181123T1 (hr) | Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac | |
IL256589B (en) | 7,4,2-trimethyloct-6-en-1-ol as a fragrance component | |
SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
GB201604865D0 (en) | Patient fall prevention |